Certara, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, has released version 13 of its Simcyp Simulator. The solution enables the quantitative prediction of drug-drug-interactions and pharmacokinetic-pharmacodynamic outcomes in virtual populations.
Features include a full physiologically-based pharmacokinetic (PBPK) model for monoclonal antibodies and therapeutic proteins with significant practical applications, and the inclusion of a non-linear plasma protein and red blood cell binding facility. Furthermore, the integration of a novel sophisticated IVIVC tool to handle in vitro - in vivo correlations of dissolution for various solid oral dosage forms enhances the scope of the simulator in the divisions of formulation and pharmaceutics.
